NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Novel muramyl tripeptide (MTP-PE) adjuvant formulations for enhancement of immunity to recombinant HIV-1 gp120 envelope antigens.

Van Nest G, Barchfeld G, Haigwood N, Ott G, Wentworth P, Steimer K; International Conference on AIDS.

Int Conf AIDS. 1990 Jun 20-23; 6: 326 (abstract no. 1050).

Chiron Corporation, Emeryville, California, USA

OBJECTIVE: To develop adjuvant formulations suitable for human vaccine use that surpass alum in their ability to enhance immunity to HIV-1 subunit immunogens. METHODS: A series of adjuvant formulations consisting of MTP-PE in metabolizable oil emulsions have been compared to conventional adjuvants such as alum and Freund's. Experimental animals were immunized with recombinant HIV-1 gp120 antigens (both non-glycosylated denatured and fully glycosylated native versions) in the various formulations, their sera were tested for ELISA-reactive and virus neutralizing antibodies and their helper T cell responses were assessed by lymphoproliferative assays. RESULTS: Most of these novel adjuvant formulations were effective in guinea pigs, mice and rabbits. However, the properties of the emulsion dramatically influenced the efficacy of these formulations in larger animals such as goats and baboons. One new formulation was as effective as Freund's incomplete adjuvant and was also at least 10-fold more effective than alum in enhancing antibody responses, neutralizing antibody titers and lymphoproliferative responses to recombinant gp120 antigens in large animals. CONCLUSIONS: Improved adjuvants with the potential of enhancing immune responses to recombinant HIV-1 gp120 antigens in humans have been developed. Further immunogenicity studies and extensive safety trials with these formulations are in progress.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acetylmuramyl-Alanyl-Isoglutamine
  • Adjuvants, Immunologic
  • Adjuvants, Pharmaceutic
  • Alum Compounds
  • Animals
  • Antibody Formation
  • Antigens
  • Antigens, Viral
  • Enzyme-Linked Immunosorbent Assay
  • HIV Envelope Protein gp120
  • HIV-1
  • Humans
  • Mice
  • Phosphatidylethanolamines
  • Rabbits
  • aluminum sulfate
  • immunology
  • muramylNAc-Ala-isoGln-Lys-tripeptide
  • muramylNAc-Ala-isoGln-Lys-tripeptide-PE
Other ID:
  • 40105090
UI: 102196899

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov